662 Urokinase plasminogen activator, a potential prognostic marker for node-negative breast cancer

1995 ◽  
Vol 31 ◽  
pp. S139
Author(s):  
M.J. Duffy ◽  
C. Duggan ◽  
H. Mulcahy ◽  
E.W. McDermott ◽  
J.J. Fenelly ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Plasminogen Activator ◽  
Prognostic Marker ◽  
Urokinase Plasminogen Activator ◽  
Node Negative ◽  
Node Negative Breast Cancer

scholarly journals Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease

1998 ◽  
Vol 44 (6) ◽  
pp. 1177-1183 ◽  
Author(s):  
Michael J Duffy ◽  
Catherine Duggan ◽  
Hugh E Mulcahy ◽  
Enda W McDermott ◽  
Niall J O’Higgins
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Plasminogen Activator ◽  
Prognostic Marker ◽  
Urokinase Plasminogen Activator ◽  
Lymph Node Status ◽  
Disease Free Interval ◽  
Node Negative ◽  
Free Interval ◽  
Disease Free

Abstract Urokinase plasminogen activator (uPA) is a serine protease causally involved in cancer invasion and metastasis. In this study, high concentrations of uPA in primary breast cancers were independently associated with both a shortened disease-free interval and overall survival. For the disease-free interval as endpoint, uPA was a stronger indicator of outcome than lymph node status, whereas for overall survival, nodal status was stronger than uPA. In patients without metastasis to axillary nodes, uPA was also an independent prognostic marker, using both the disease-free interval and overall survival as end points. In contrast to uPA, neither tumor size nor estrogen receptor status was prognostic in the node-negative patients. Measurement of uPA concentrations might thus be of value in selecting the more aggressive subpopulation of node-negative breast cancer patients that could benefit from adjuvant therapy.

scholarly journals Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer

2000 ◽  
Vol 15 (1) ◽  
pp. 73-78 ◽  
Author(s):  
A. Prechtl ◽  
N. Harbeck ◽  
C. Thomssen ◽  
C. Meisner ◽  
M. Braun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Systemic Therapy ◽  
Axillary Node ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Pai 1

In axillary node-negative primary breast cancer, 70% of the patients will be cured by locoregional treatment alone. Therefore, adjuvant systemic therapy is only needed for those 30% of node-negative patients who will relapse after primary therapy and eventually die of metastases. Traditional histomorphological and clinical factors do not provide sufficient information to allow accurate risk group assessment in order to identify node-negative patients who might benefit from adjuvant systemic therapy. In the last decade various groups have reported a strong and statistically independent prognostic impact of the serine protease uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 (plasminogen activator inhibitor type 1) in node-negative breast cancer patients. Based on these data, a prospective multicenter therapy trial in node-negative breast cancer patients was started in Germany in June 1993, supported by the German Research Association (DFG). Axillary node-negative breast cancer patients with high levels of either or both proteolytic factors in the tumor tissue were randomized to adjuvant CMF chemotherapy versus observation only. Recruitment was continued until the end of 1998, by which time 684 patients had been enrolled. Since then, patients have been followed up in order to assess the value of uPA and PAI-1 determination as an adequate selection criterion for adjuvant chemotherapy in node-negative breast cancer patients. This paper reports on the rationale and design of this prospective multicenter clinical trial, which may have an impact on future policies in prognosis-oriented treatment strategies.

scholarly journals Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study

2015 ◽  
Vol 54 (4) ◽  
pp. 543-549 ◽  
Author(s):  
Claudia Lundgren ◽  
Cecilia Ahlin ◽  
Lars Holmberg ◽  
Rose-Marie Amini ◽  
Marie-Louise Fjällskog ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Prognostic Marker ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Node Negative ◽  
Cyclin E1 ◽  
Node Negative Breast Cancer ◽  
Control Study

scholarly journals Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Catherine L. Forse ◽  
Seema Agarwal ◽  
Dushanthi Pinnaduwage ◽  
Frank Gertler ◽  
John S. Condeelis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Quantitative Method ◽  
Axillary Node ◽  
Node Negative ◽  
Node Negative Breast Cancer

scholarly journals Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Node–Negative Breast Cancer Patients

2006 ◽  
Vol 12 (11) ◽  
pp. 3319-3328 ◽  
Author(s):  
Anieta M. Sieuwerts ◽  
Maxime P. Look ◽  
Marion E. Meijer-van Gelder ◽  
Mieke Timmermans ◽  
Anita M.A.C. Trapman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Cyclin E ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer

S-Phase Fraction and Urokinase Plasminogen Activator Are Better Markers for Distant Recurrences Than Nottingham Prognostic Index and Histologic Grade in a Prospective Study of Premenopausal Lymph Node–Negative Breast Cancer

2001 ◽  
Vol 19 (7) ◽  
pp. 2010-2019 ◽  
Author(s):  
P. Malmström ◽  
P-O. Bendahl ◽  
P. Boiesen ◽  
N. Brünner ◽  
I. Idvall ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Plasminogen Activator ◽  
Prognostic Index ◽  
Distant Recurrence ◽  
Nottingham Prognostic Index ◽  
Histologic Grade ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Pai 1

PURPOSE: Histologic grade, Nottingham Prognostic Index (NPI), estrogen receptor (ER) and progesterone receptor (PgR) status, and tumor size have previously been shown to be important prognostic indicators for distant recurrence of breast cancer. The purpose of this study was to compare the prognostic value of these factors with flow cytometric S-phase fraction (SPF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor type 1 (PAI-1) in premenopausal patients with lymph node–negative breast cancer. PATIENTS AND METHODS: In 237 consecutive premenopausal patients with lymph node–negative breast cancer and freshly frozen tumor material available, SPF, ER and PgR status, uPA and its inhibitor PAI-1, histologic grade, and NPI were evaluated. RESULTS: SPF was univariately the most powerful prognostic factor for distant recurrence, followed by uPA, histologic grade, PgR, age, ER, NPI, and PAI-1, the latter being nonsignificant. Multivariate analysis revealed that neither NPI nor histologic grade was significant after adjustment for SPF, a fact that may be explained by the strong association between these factors. uPA was, however, an independent prognostic factor in addition to SPF, NPI, or histologic grade. CONCLUSION: In this prospective study, SPF and uPA were found to be independent prognostic factors in premenopausal women with lymph node–negative breast cancer. We suggest that SPF, if performed under standardized conditions, can replace histologic grade as a selection instrument for adjuvant medical treatment. The value of the combination of SPF and uPA needs to be confirmed in an independent prospective trial.

Sign in / Sign up

Export Citation Format

Share Document